Compare ZTO & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTO | VTRS |
|---|---|---|
| Founded | 2002 | 1961 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 14.2B |
| IPO Year | 2016 | N/A |
| Metric | ZTO | VTRS |
|---|---|---|
| Price | $22.62 | $12.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 6 |
| Target Price | ★ $21.90 | $11.50 |
| AVG Volume (30 Days) | 1.3M | ★ 9.3M |
| Earning Date | 11-19-2025 | 02-26-2026 |
| Dividend Yield | 2.67% | ★ 3.65% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | $6,673,175,085.00 | ★ $14,124,400,000.00 |
| Revenue This Year | $12.15 | N/A |
| Revenue Next Year | $11.36 | $1.18 |
| P/E Ratio | $19.40 | ★ N/A |
| Revenue Growth | ★ 13.17 | N/A |
| 52 Week Low | $16.34 | $6.85 |
| 52 Week High | $22.69 | $13.49 |
| Indicator | ZTO | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 70.13 | 64.40 |
| Support Level | $21.33 | $12.53 |
| Resistance Level | $22.26 | $13.49 |
| Average True Range (ATR) | 0.34 | 0.31 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 92.39 | 50.77 |
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 19.4% in 2024. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 78% voting rights as of March 31, 2025. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 8.9% interest.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.